Amicus Therapeutics, Inc. (NASDAQ:FOLD) Position Cut by Vontobel Holding Ltd.

Vontobel Holding Ltd. cut its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 29.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 50,435 shares of the biopharmaceutical company’s stock after selling 20,575 shares during the quarter. Vontobel Holding Ltd.’s holdings in Amicus Therapeutics were worth $475,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Wellington Management Group LLP boosted its stake in shares of Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after acquiring an additional 2,856,101 shares in the last quarter. Geode Capital Management LLC raised its holdings in Amicus Therapeutics by 1.2% during the third quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock valued at $70,499,000 after buying an additional 80,926 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Amicus Therapeutics by 4.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock valued at $33,749,000 after buying an additional 139,491 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Amicus Therapeutics by 10.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after purchasing an additional 242,672 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Amicus Therapeutics by 141.1% in the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock worth $21,765,000 after purchasing an additional 1,192,489 shares during the period.

Analysts Set New Price Targets

FOLD has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. JPMorgan Chase & Co. boosted their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Guggenheim boosted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $9.07 on Friday. The firm has a market cap of $2.71 billion, a PE ratio of -26.68, a PEG ratio of 1.65 and a beta of 0.61. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. Amicus Therapeutics, Inc. has a 1-year low of $8.78 and a 1-year high of $14.02. The company has a fifty day moving average price of $9.56 and a 200 day moving average price of $10.41.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.